College-based research labs are the workhorses of national progress and prosperity. Carole LaBonne is the Erastus Otis Haven ...

As the United States cuts budgets and restricts immigration, China and Europe are offering researchers money and stability.

Labor’s historic election victory has given them a rare licence to invest in a better, more exciting future. For Albanese and ...

The federal government’s role is not to chase quarterly returns. It is to invest in generational outcomes. Slashing investments for ideological reasons is shortsighted. And the damage may not be ...

There's no reason the U.S. can't pick up the pace to match the global clinical research front-runners without compromising ...

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for $9.5 billion, sending shares of the ...

Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer ...

After a back and forth with two potential buyers, bluebird bio has completed its sale to funds managed by global investment ...

U.S.-listed shares of BioNTech jumped more than 15% Monday morning after the German vaccine maker announced a collaboration ...

Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, ...

The investment comes as the FDA is pushing drug developers to phase out animal testing in some of the biologic treatments ...

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...